Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03546673 Completed - Breast Cancer Clinical Trials

Health Benefits of Expressive Writing: Study One

Start date: July 2009
Phase: N/A
Study type: Interventional

This study is a randomized controlled trial (RCT) with the aim of determining the cultural sensitivity, feasibility, and effectiveness of an expressive writing intervention for Chinese breast cancer survivors.

NCT ID: NCT03546478 Completed - Breast Cancer Clinical Trials

99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization

Start date: June 24, 2015
Phase: Early Phase 1
Study type: Interventional

This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the diagnostic performance and evaluation efficacy of 99mTc-ABH2 in breast cancer patients. A single dose of 370±54 Mega-Becquerel (MBq)99mTc-ABH2 will be injected intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.

NCT ID: NCT03541161 Completed - Breast Cancer Clinical Trials

Early Rehabilitation After Immediate Reconstruction With TEI in Breast Cancer Patients

Start date: May 2016
Study type: Observational

The purpose of the study is to find best post-operative rehabilitation protocol after total mastectomy and immediate reconstruction with tissue expander insertion. This study compared outcomes of two post-operative rehabilitation protocols ; "conventional protocol", which immobilized shoulder and upper arm motion for a month and "early rehabilitation protocol" with short-term immobilization period and early mobilization.

NCT ID: NCT03530722 Completed - Breast Cancer Clinical Trials

Ex-vivo Performance Evaluation of the Histolog™ Scanner for Human Breast Carcinoma Detection on Fresh Breast Core Biopsies

Start date: July 4, 2017
Study type: Observational

Fresh breast core biopsies suspicious for breast cancer that are usually taken during clinical breast assessments will be imaged via confocal microscopy. The device so called HistologTM Scanner is based on confocal fluorescence and displays microscopic histology images superficial layers of fresh tissue. After the imaging procedure the fresh breast tissue specimen will be followed according to the gold standard workflow (H&E-stained images). Subsequently, two pathologists will analyze the HistologTM Scanner obtained-images and H&E-stained images for potential breast cancer structures. A comparison of both analyses for cancer visualization will be performed to evaluate the feasibility of using confocal microscopy for breast cancer detection.

NCT ID: NCT03491917 Completed - Breast Cancer Clinical Trials

Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer

Start date: November 3, 2017
Phase: N/A
Study type: Interventional

The purpose of this pilot is to provide credible performance estimate information in order to conduct a subsequent pivotal reader study.

NCT ID: NCT03471741 Completed - Breast Cancer Clinical Trials

Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer

Start date: June 1, 2001
Study type: Observational

To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk breast cancer in terms of late toxicity and local control

NCT ID: NCT03461224 Completed - Breast Cancer Clinical Trials

Modulated Accelerated RAdiotherapy in Early Breast Cancer

Start date: January 10, 2001
Phase: N/A
Study type: Observational

This trial was a retrospective study on postoperative accelerated hypofractionated IMRT (MARA-1) in patients with early stage breast carcinoma, to compare late toxicity after this treatment and standard fractionated RT delivered with 3D-CRT.

NCT ID: NCT03456427 Completed - Breast Cancer Clinical Trials

Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow

Start date: January 4, 2018
Phase: N/A
Study type: Interventional

Patient-assisted compression (PAC) allows the patient to participate in controlling the amount of compression force during mammography and is a personalized approach that has demonstrated successful reduction in discomfort experienced during mammography. GE Healthcare's Senographe Pristina, an innovative mammography platform that provides both two-dimensional (2D) and three-dimensional (3D) imaging capabilities, offers both standard and patient-assisted compression modes. This study will evaluate image quality and clinical workflow as it relates to use of PAC with the Senographe Pristina 3D.

NCT ID: NCT03428789 Completed - Breast Cancer Clinical Trials

Nerve Coaptation in DIEP Flap Breast Reconstruction

Start date: September 2015
Phase: N/A
Study type: Observational

The sensory recovery of the breast remains an undervalued aspect of breast reconstruction and surgical reinnervation is not regarded as a priority by most reconstructive surgeons. A prospective study was conducted of all patients who underwent either innervated or non-innervated DIEP flap breast reconstruction in Maastricht University Medical Center and returned for follow-up between September 2015 and July 2017. Semmes-Weinstein monofilaments were used for sensory testing of the breast. This study showed that nerve coaptation in DIEP flap breast reconstruction resulted in a significantly improved sensation of the reconstructed breast compared to non-innervated flaps.

NCT ID: NCT03419026 Completed - Breast Cancer Clinical Trials

Pregnant Exposure to Persistent Organic Pollutants

Start date: May 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

Breast cancer, the first female cancer, affects one in eight women in her lifetime. The increase and uneven distribution of its prevalence throughout the world cannot be fully explained either by the increase in life expectancy, or by genetic factors present in less than 10% of cases, or by early detection, or by the use of hormone therapy for menopause at certain periods of time. Numerous experimental and epidemiological arguments, as well as the increased risk of breast cancer in women after 50 years of age who were exposed in utero to Distilbene prescribed for their mothers in the 1950s to 75's, suggest the involvement of environmental factors involved in early development (nutrition, alcohol, tobacco, chemical pollutants) that may act as endocrine disruptors, estrogenomimetic or intervening on other nuclear receptors such as the However, the formal demonstration of the deleterious physiopathological role of such exposure comes up against methodological difficulties in epidemiological terms: first of all, the fact that correlation is sought at the time of the discovery of breast cancer when there are critical windows of exposure (fetal, perinatal, peripubertal and pregnant) and that persistent organic products or POPs, most often lipids, are present. The objective of this project is to correlate the per-gravidic exposure to POPs (dioxins, dioxinlike, polychlorinated bisphenyls, organochlorine pesticides and flame-retardant polybrominated derivatives) and the development, within 15 years of delivery, of breast cancer, taking into account the confounding factors of classical breast cancer risk (age, reproductive events, etc.). This project benefits on the one hand from a cord blood bank set up between 2002 and 2005 (6,242 samples) carried out at the Nice University Hospital and the Grasse University Hospital, during a PHRC and on the other hand from the cancer observatory / CRISAP of the PACA Corsica region, exhaustive to more than 92% since 2005, registers which will be cross-referenced and whose cancer cases (N) will be compared to controls. The assays will be carried out after purification, using high-resolution mass spectrometry gas chromatography coupling, the quantification being carried out according to the principle of isotopic dilution. They will be carried out by LABERCA in Nantes, the national reference laboratory of the French Health Agencies ANSES and INVS and also involved in various European projects. Concentrations related to blood lipids will be expressed in quartile and analyzed separately or combined with a cumulative score taking into account confounding risk factors for breast cancer and the geolocation of the initial and final residence in relation to the incinerator of the City of Nice (Department of Public Health CHU of Nice).